

Company registration number: SC392237
Charity registration number: SC042061

**FUNDING NEURO
TRUSTEES' REPORT AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

Donn Sheldon
21 Forbes Place
Paisley
PA1 1UT

Funding Neuro Contents

	Page
Trustees' Report	1—4
Independent Examiner's Report	5
Statement of Financial Activities (including Income and Expenditure Account)	6
Comparative Statement of Financial Activities (including Income and Expenditure Account)	7
Balance Sheet	8
Notes to the Financial Statements	9—16
The following pages do not form part of the statutory accounts:	
Detailed Statement of Financial Activities (including Income and Expenditure Account)	17—18

Funding Neuro
Company No. SC392237
Trustees' Report For The Year Ended 31 December 2025

The trustees present their report and the financial statements for the year ended 31 December 2025.

Objectives and Activities

Aims and Objectives

The charity's objectives are to advance health, science and education, and to relieve those who are in need by reason of their suffering from a condition of the brain and/or spinal column. This is achieved through raising funds for projects (including research-based projects) relating to the treatment, through improved medication delivery systems or therapeutic device delivery systems, of conditions affecting the brain and spinal column.

The charity was established to improve the delivery of medication and therapeutic devices to the brain. In any trial in which medication is delivered inside the blood brain barrier, the results are dependent on the effective delivery of the medication and the efficacy of the medication. When analysing the results, particularly if the outcome is unexpected, it is often impossible to determine if whether this is due to the efficacy of the medication or whether the medication was delivered to where it can be most effective.

Alongside that, there is a need to raise awareness of neurological conditions and the common problem of delivery which exists. Our aim is to accelerate the development of new treatments for many of the most serious neurological conditions. We do not focus on one single neurological condition, nor do we seek to duplicate the work being carried out by other charities. Instead, we identify the issues that hinder progress and find solutions so that research and innovative therapies can be accelerated.

To do this we need to ensure that promising clinical research can find its way out of the lab and to the patient in the treatment room. By focusing on translating breakthrough research into breakthrough treatments we believe we can revolutionise the effectiveness of neurological care.

The policies adopted in furtherance of these objects are to recruit fundraisers to participate in events organised by others, to raise funds and to raise awareness. The charity also stages awareness and fundraising events in its own name such as dinners and assists others in staging similar events, such as golf days in support of the charity.

There has been no change in the policies during the period. The trustees have paid due regard to guidance issued by the Office of the Scottish Charity regulator in deciding what activities the charity should undertake.

Throughout the year the trustees consider opportunities to provide grant funding to research projects and treatments in line with the charitable objectives of the charity. Formal policies and procedures are now in place for the recruitment and induction of trustees, including a code of conduct and role descriptions.

Achievements and Performance

Main Achievements

During 2025, the year under review, Funding Neuro continued to maintain and strengthen relationships with other charities and governmental bodies to improve the delivery of much needed clinical trials in the Neurological area. Funding Neuro had a number of meetings with the UK Focussed Ultrasound Foundation as we believe this will provide us with opportunities to work in areas of mutual interest.

The largest grant made available during 2025 was of £75,000 to Professor Wladyslaw Gedroyc of St Mary's Hospital, Paddington (following a £120,000 grant to fund an academic neuroradiologist for a three year period in 2024, Dr Ayesha Jameel). The latest grant will be made via the Focussed Ultrasound Foundation as part of a three charity group to conduct a safety trial to prove the safety and efficacy of a drug/device GBM trial.

Progress at Great Ormond Street Hospital in respect of a DIPG trial is ongoing with seven patients enlisted of the target twelve and a number of useful learnings are coming from the trial.

As well as seeking treatments for Neurological Conditions Funding Neuro has maintained a healthy dialogue with the medical community through its membership of the Neurological Alliance of Scotland where have continued to lobby for more funding for Neurological research. Funding Neuro joined the Board of Trustees of this body in an effort to promote the need for increased Neurological research in 2024 and became Vice-Chair in 2025.

As ever none of our work would be possible without the invaluable support of our donors and fundraisers. Special mention needs to be made of the Bucks Bar and Thundercat for hosting and participating so enthusiastically in the Ladies Lunch as well as every major Funding Neuro event. During 2025 we also received the support of RUSHfest Scotland, who agreed to support Funding Neuro with donations from record sales and an annual music event and this will continue in 2026 and 2027.

...CONTINUED

**Funding Neuro
Trustees' Report (continued)
For The Year Ended 31 December 2025**

Main Achievements - continued

And finally, a massive thank you to all the fundraisers and donors who took part in so many different fundraising events and activities, large and small in the year. We never under-estimate the effort you put in and look forward to delivering for you together in the coming years.

Financial Review

Financial Position

During the year the charity has recorded a deficit of £177,640 (2024: £2,718) and held net assets of £425,956 (2024: £603,596) at 31 December 2025. Net assets at 31 December 2025 include £245,596 (2024: £351,615) of restricted funds to help fund clinical trials. There are also designated funds of £100,034 (2024: £179,994) in relation to Daisy Donations and the Charlie Stephenson fund, with other unrestricted funds of £80,326 (2024: £71,987).

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six months expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

The charity's reserves policy is based on the minimum required to operate the charity. This would mainly consist of salaries for staff and the cost of communications. This is approximately £6,000 per month, therefore at the year end the charity was operating with over six months reserves. Management and the trustees continue to identify measures to ensure the unrestricted reserves remain in line with the policy.

In addition, we have continued to build relationships with other charities with the aim of building joint funding neurological research and concerns to increase funding in neurological research.

Going Concern

Unrestricted reserves have decreased to £180,360, however, with a reduced cost base and the recommencement of a full fundraising programme the trustees consider that it remains appropriate to adopt the going concern assumption in the preparation of the financial statements.

Risk Assessment

The main risk the charity faced from an operational stand point was that it was wholly dependent on voluntary income, but in particular on the success of the increasing number of fundraising events organised with the charity's control. The charitable company had been successful in strategies to mitigate the risk, however the continuing cost of living crisis has reduced the ability of the charitable company to undertake its normal level of fundraising.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks, while recognising, as set out earlier, the specific financial challenges arising from the cost of living crisis to the charitable company.

Structure, Governance and Management

Governing Document

The charity is a company limited by guarantee and is governed by its Articles of Association.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

M Howick
B Williams
G McMeechan
T Bruce

The legal and administrative information attached to these accounts forms part of this report.

As detailed in the Articles of Association of the company, each member of the charity is automatically appointed a trustee. Membership is open to any individual over the age of 18 who wishes to support the aims and activities of the company and who has been nominated for membership by two trustees of the company. The resolution to admit any person to the membership shall be effective only if at least two thirds of the trustees then in office vote in favour of that resolution. Any individual, once admitted to membership, shall remain a member until he/she submits a written notice of retiral.

...CONTINUED

**Funding Neuro
Trustees' Report (continued)
For The Year Ended 31 December 2025**

Governing Document - continued

None of the trustees have any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The day-to-day operation of the charity is undertaken by the Chief Executive with input where required from the trustees. Over and above that, the charity trustees meet on a quarterly basis to discuss the activities of the charity particularly with regard to the allocation of grant funding, fundraising activities, alignment of activities with the objectives of the charity and risk management.

The charity responds to appeals from other charities for the grant funding of projects which require capital investment, and which fall in line with the objectives of the charity. The charity believes that going forward it will be necessary to work with other charities to fund projects.

Pay and remuneration for key management personnel are set by benchmarking, including with reputable specialist recruitment agencies, against other organisations of a similar structure and size, as appropriate.

There are no relationships with related parties that are relevant to the pursuit of the charitable objectives.

The trustees are responsible for the maintenance and integrity of the corporation and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

Reference and Administrative Details

Trustees

Mr Matthew Howick
Mrs Theresa Bruce
Mr Gregor McMeechan
Mr Brynley Williams

Charity Number

SC042061

Company Number

SC392237

Registered Office

Suite 107, Central Chambers
109 Hope Street
Glasgow
G2 6LL

Independent Examiner

Michael Benham CA
Benham Conway & Co
16 Royal Crescent
Glasgow
G3 7SL

**Funding Neuro
Trustees' Report (continued)
For The Year Ended 31 December 2025**

Post Balance Sheet Events

Since the year end we have allocated the following funds:

- £120,000 for a 3 year research assistant. The work being done is about general focussed ultrasound opening of blood brain barrier and will help DIPG. The funds are from the Charlie Stephenson Fund and the DIPG Clinical Trial Fund.
- £75,000 for a GBM trial. The funds are from the Glioblastoma Fund.

Small Company Rules

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The trustees' report was approved by the board of trustees and signed on its behalf by:

Mr Matthew Howick
Trustee
Date 10 August 2026



Funding Neuro
Independent Examiner's Report to the Trustees of Funding Neuro
For The Year Ended 31 December 2025

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.

Responsibilities and Basis of Report

As the charity trustees of the Company (and also its directors for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The charity trustees consider that the audit requirement of Regulation 10(1) (a) to (c) of the 2006 Accounts Regulations does not apply. It is my responsibility to examine the accounts as required under section 44(1) (c) of the Act and to state whether particular matters have come to my attention.

My examination is carried out in accordance with Regulation 11 of the 2006 Accounts Regulations. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeks explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently I do not express an audit opinion on the view given by the accounts.

Independent Examiner's Statement

Since the Charity has prepared its accounts on an accruals basis and is registered in Scotland your examiner must be a member of a body listed in Regulation 11(2) of the Charities Accounts (Scotland) Regulations 2006 (as amended). I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants of Scotland, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act and Regulation 4 of the Charities Accounts (Scotland) Regulations 2006 (as amended); or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view', which is not a matter considered as part of an Independent Examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic or Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Michael Benham CA
Date **12 August 2026**
Benham Conway & Co
16 Royal Crescent
Glasgow
G3 7SL

Funding Neuro
Statement of Financial Activities (including Income and Expenditure Account)
For The Year Ended 31 December 2025

				2025	2024
		Unrestricted funds	Restricted funds	Total funds	Total funds
	Notes	£	£	£	£
INCOME AND ENDOWMENTS FROM:					
Donations and legacies	3	32,596	8,981	41,577	46,980
Other trading activities	4	67,334	-	67,334	36,514
Investments	5	6,410	-	6,410	6,947
		<u>106,340</u>	<u>8,981</u>	<u>115,321</u>	<u>90,441</u>
EXPENDITURE ON:					
Raising funds	7	(36,881)	-	(36,881)	(30,746)
Charitable activities:	7				
Grants to clinical trials		(80,000)	(115,000)	(195,000)	-
Share of support costs		(55,540)	-	(55,540)	(54,290)
Governance costs		(5,540)	-	(5,540)	(8,122)
		<u>(177,961)</u>	<u>(115,000)</u>	<u>(292,961)</u>	<u>(93,158)</u>
NET EXPENDITURE		<u>(71,621)</u>	<u>(106,019)</u>	<u>(177,640)</u>	<u>(2,717)</u>
NET MOVEMENT IN FUNDS		<u>(71,621)</u>	<u>(106,019)</u>	<u>(177,640)</u>	<u>(2,717)</u>
RECONCILIATION OF FUNDS:					
Total funds brought forward		251,981	351,615	603,596	606,313
TOTAL FUNDS CARRIED FORWARD	15	<u>180,360</u>	<u>245,596</u>	<u>425,956</u>	<u>603,596</u>

The notes on pages 9 to 16 form part of these financial statements.

Funding Neuro
Comparative Statement of Financial Activities (including Income and Expenditure Account)
For The Year Ended 31 December 2025

				2024
		Unrestricted funds	Restricted funds	Total funds
	Notes	£	£	£
INCOME AND ENDOWMENTS FROM:				
Donations and legacies	3	37,608	9,372	46,980
Other trading activities	4	36,514	-	36,514
Investments	5	6,947	-	6,947
		<u>81,069</u>	<u>9,372</u>	<u>90,441</u>
EXPENDITURE ON:				
Raising funds	7	(28,469)	(2,277)	(30,746)
Charitable activities:	7			
Share of support costs		(54,290)	-	(54,290)
Governance costs		(8,122)	-	(8,122)
		<u>(90,881)</u>	<u>(2,277)</u>	<u>(93,158)</u>
NET EXPENDITURE		<u>(9,812)</u>	<u>7,095</u>	<u>(2,717)</u>
NET MOVEMENT IN FUNDS		<u>(9,812)</u>	<u>7,095</u>	<u>(2,717)</u>
RECONCILIATION OF FUNDS:				
Total funds brought forward		261,793	344,520	606,313
TOTAL FUNDS CARRIED FORWARD	15	<u>251,981</u>	<u>351,615</u>	<u>603,596</u>

The notes on pages 9 to 16 form part of these financial statements.

**Funding Neuro
Balance Sheet
As At 31 December 2025**

				2025	2024
		Unrestricted funds	Restricted funds	Total funds	Total funds
	Notes	£	£	£	£
FIXED ASSETS					
Intangible Assets	11	3,556	-	3,556	4,125
		3,556	-	3,556	4,125
CURRENT ASSETS					
Debtors	13	2,650	-	2,650	1,000
Cash at bank and in hand		620,891	-	620,891	605,446
		623,541	-	623,541	606,446
Creditors: Amounts Falling Due Within One Year	14	(86,141)	(115,000)	(201,141)	(6,975)
NET CURRENT ASSETS (LIABILITIES)		537,400	(115,000)	422,400	599,471
TOTAL ASSETS LESS CURRENT LIABILITIES		540,956	(115,000)	425,956	603,596
NET ASSETS		540,956	(115,000)	425,956	603,596
FUNDS OF THE CHARITY					
Restricted Funds				245,596	351,615
Unrestricted Funds				180,360	251,981
TOTAL FUNDS	15			425,956	603,596

For the year ending 31 December 2025 the charitable company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

On behalf of the board



Mr Matthew Howick
Trustee

Date 10 August 2026

The notes on pages 9 to 16 form part of these financial statements.

Funding Neuro
Notes to the Financial Statements
For The Year Ended 31 December 2025

1. General Information

Funding Neuro is a company limited by guarantee, incorporated in Scotland, registered number SC392237 and registered charity number SC042061. The registered office is Suite 107, Central Chambers, 109 Hope Street, Glasgow, G2 6LL.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)", Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The charitable company is a Public Benefit Entity as defined by FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

The accounts have been prepared on the historical cost convention. The principal accounting policies adopted are set out below.

The company has availed itself of section 396 of the Companies Act 2006, as permitted in paragraph 4(1) of Schedule 1 of SI 2008 no 409, and adapted the Companies Act formats to reflect the special nature of its charitable activities.

2.2. Going Concern Disclosure

These financial statements are prepared on the going concern basis. The trustees have a reasonable expectation that the charitable company will continue in operational existence for at least 12 months from date of approval of the financial statements.

Subsequent to the year end, the charitable company has continued to generate unrestricted donations to cover its monthly running costs and allow the trustees to continue their work towards medical trial activity.

Consideration of the cashflow budgets for 2026 and beyond mean that while there can be no certainty on the receipt of future unrestricted donations, the trustees have not identified any material uncertainty as to the charitable companies going concern position.

2.3. Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees in furtherance of the charity's objectives unless the funds have been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the trustees for specific purposes. The purposes and users of the designated funds are set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

2.4. Incoming Resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy.

Cash donations are recognised on receipt. Other donations are recognised once the charitable company has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charitable company has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Donated professional services and donated facilities are recognised as income when the company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general time of the volunteers is not recognised.

...CONTINUED

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

2.4. Incoming Resources - continued

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the company which is the amount the company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in the expenditure in the period of receipt.

Volunteers assist at fundraising events run by Funding Neuro by collecting donations or assisting with the fundraising activity. Donated goods and services include rent, donated trial devices, printing, advertising and other general running expenses.

Investment income is recognised on an accruals basis.

Income from other trading activities is measured at fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts.

Where any income debtor is impaired because it is doubtful that full settlement will be received, an adjustment is made to reduce the debtor and the corresponding line where the income was originally recorded.

2.5. Resources Expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure is classified under the following activity headings:

- Expenditure of charitable activities includes activities undertaken to further the purpose of the charity and their associated support costs
- Expenditure on raising funds represents the costs of income from other trading activities.

2.6. Intangible Fixed Assets and Amortisation - Other Intangible

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Website costs 10 years straight line

2.7. Tangible Fixed Assets and Depreciation

At each reporting end date, the charitable company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

2.8. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

2.9. Financial Instruments

Basic financial assets, which include debtors and cash and bank balances, are measured at transaction price including transaction costs.

Basic financial liabilities, including creditors, are recognised at transaction price.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment due within one year or less.

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

2.10. Employee Benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charitable company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

3. Income from Donations and Legacies

	Unrestricted funds	Restricted funds	2025 Total funds
	£	£	£
Donations and gifts	26,781	8,559	35,340
Gift aid	815	422	1,237
Grants	5,000	-	5,000
	32,596	8,981	41,577

	Unrestricted funds	Restricted funds	2024 Total funds
	£	£	£
Donations and gifts	24,680	7,887	32,567
Gift aid	2,928	1,485	4,413
Grants	10,000	-	10,000
	37,608	9,372	46,980

4. Income from Other Trading Activities

	2025 Unrestricted funds	2024 Unrestricted funds
	£	£
Fundraising events	67,334	36,514

5. Investment Income

	2025 Unrestricted funds	2024 Unrestricted funds
	£	£
Bank interest receivable	6,410	6,947

6. Net Income/(Expenditure)

The net expenditure is stated after charging/(crediting):

	2025 £	2024 £
Amortisation of intangible fixed assets	569	569

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

7. Analysis of Expenditure

	2025		
	Activities undertaken directly	Grant funding of activities	Support costs (see note 8)
	£	£	£
Raising funds	36,881	-	-
Grants to clinical trials	-	195,000	-
Share of support costs	-	-	55,540
Governance costs	-	-	5,540
	36,881	195,000	61,080
	36,881	195,000	292,961

	2024		
	Activities undertaken directly	Support costs (see note 8)	Total
	£	£	£
Raising funds	30,746	-	30,746
Share of support costs	-	54,290	54,290
Governance costs	-	8,122	8,122
	30,746	62,412	93,158

8. Support Costs

	2025		
	Share of support costs	Governance costs	Total
	£	£	£
Employee costs	51,587	-	51,587
Premises expenses	1,024	-	1,024
General administration	2,929	4,971	7,900
Depreciation	-	569	569
	55,540	5,540	61,080

	2024		
	Share of support costs	Governance costs	Total
	£	£	£
Employee costs	48,840	-	48,840
Premises expenses	956	-	956
General administration	4,494	7,553	12,047
Depreciation	-	569	569
	54,290	8,122	62,412

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

9. Staff Costs

Staff costs were as follows:

	2025	2024
	£	£
Wages and salaries	51,467	48,840
Other pension costs	120	-
	<u>51,587</u>	<u>48,840</u>

No employees received employee benefits (excluding employer pension costs) for the reporting period of more than £60,000.

10. Average Number of Employees

Average number of employees during the year was: 2 (2024: 2)

11. Intangible Assets

	Other £
Cost	
As at 1 January 2025	5,688
As at 31 December 2025	<u>5,688</u>
Amortisation	
As at 1 January 2025	1,563
Provided during the period	569
As at 31 December 2025	<u>2,132</u>
Net Book Value	
As at 31 December 2025	<u>3,556</u>
As at 1 January 2025	<u>4,125</u>

12. Tangible Assets

	Computer Equipment £
Cost	
As at 1 January 2025	8,837
As at 31 December 2025	<u>8,837</u>
Depreciation	
As at 1 January 2025	8,837
As at 31 December 2025	<u>8,837</u>
Net Book Value	
As at 31 December 2025	-
As at 1 January 2025	<u>-</u>

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

13. Debtors

	2025	2024
	£	£
Due within one year		
Trade debtors	2,650	1,000

14. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Taxation and social security	1,421	2,475
Accruals and deferred income	4,720	4,500
Accruals for grants payable	195,000	-
	<u>201,141</u>	<u>6,975</u>

15. Movement in Funds

	As at 1 January 2025	Income	Expenditure	As at 31 December 2025
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	71,987	106,300	(97,961)	80,326
Designated:				
Charlie Stephenson Fund	99,716	-	(80,000)	19,716
The Daisy Donations Fund	80,278	40	-	80,318
	<u>179,994</u>	<u>40</u>	<u>(80,000)</u>	<u>100,034</u>
Total unrestricted funds	<u>251,981</u>	<u>106,340</u>	<u>(177,961)</u>	<u>180,360</u>
Restricted funds				
DIPG Clinical Trial	104,524	48	(40,000)	64,572
GDNF Parkinson Trial	146,056	25	-	146,081
Glioblastoma Trial	81,075	1,510	(75,000)	7,585
The Motor Neurone Disease Fund	19,960	2,396	-	22,356
Sonodynamic Therapy Trial Appeal for Glioblastoma with CureGMB	-	5,002	-	5,002
	<u>351,615</u>	<u>8,981</u>	<u>(115,000)</u>	<u>245,596</u>
Total restricted funds	<u>351,615</u>	<u>8,981</u>	<u>(115,000)</u>	<u>245,596</u>
Total funds	<u>603,596</u>	<u>115,321</u>	<u>(292,961)</u>	<u>425,956</u>

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

	As at 1 January 2024 £	Income £	Expenditure £	As at 31 December 2024 £
Unrestricted funds				
General:				
General unrestricted fund	78,835	81,028	(87,876)	71,987
Designated:				
Charlie Stephenson Fund	102,720	-	(3,004)	99,716
The Daisy Donations Fund	80,238	40	-	80,278
	182,958	40	(3,004)	179,994
Total unrestricted funds	261,793	81,068	(90,880)	251,981
Restricted funds				
DIPG Clinical Trial	102,888	1,636	-	104,524
GDNF Parkinson Trial	144,134	1,922	-	146,056
Glioblastoma Trial	83,352	-	(2,277)	81,075
The Motor Neurone Disease Fund	14,146	5,814	-	19,960
Total restricted funds	344,520	9,372	(2,277)	351,615
Total funds	606,313	90,440	(93,157)	603,596

The Daisy Donations Fund

The Daisy Fund relates to a fundraising appeal in memory of a child, Daisy, who lost her battle due a DIPG brain tumour. It will be used to help fund a DIPG clinical trial.

Charlie Stephenson Fund

The Charlie Stephenson Fund was created to support Charlie through his DIPG treatment. Charlie lost his battle to the tumour before his treatment began, so the funds will now be used to fund the clinical trials, with some funds going towards building a play park in his memory.

DIPG Clinical Trial

The DIPG clinical trial relates to a project undertaken in which a pioneering method of treatment for a DIPG brain tumour will be tested.

The Motor Neurone Disease Fund

The Motor Neurone Disease Fund relates to therapies which can be delivered via CED at a preclinical stage.

Glioblastoma Trial

Glioblastoma tumours have a similar structure to DIPG tumours and present similar challenges in terms of treatment. This will fund trials and research.

GDNF Parkinson Trial

The GDNF Parkinson fund is for phase three of a clinical trial which aims to prove the effectiveness of delivering the GDNF growth factor to reverse the effects of Parkinson's disease.

Sonodynamic Therapy Trial Appeal for Glioblastoma with CureGMB

The Sonodynamic Therapy Trial may not go ahead and the funds will be reallocated elsewhere.

Funding Neuro
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

16. Transactions with Trustees

None of the trustees received any remuneration or any other benefits from an employment with the charity or a related entity during the current or previous year.

No trustee expenses have been incurred.

17. Related Party Disclosures

There have been no related party transactions in the reporting period that require disclosure.

18. Company limited by guarantee

The company is limited by guarantee and has no share capital.

Every member of the company undertakes to contribute to the assets of the company, in the event of a winding up, such an amount as may be required not exceeding £1.

Funding Neuro
Detailed Statement of Financial Activities (including Income and Expenditure Account)
For The Year Ended 31 December 2025

	2025	2024
	Total funds	Total funds
	£	£
INCOME AND ENDOWMENTS FROM:		
Donations and legacies		
Donations and gifts	35,340	32,567
Gift aid	1,237	4,413
Grants	5,000	10,000
	41,577	46,980
Other trading activities		
Fundraising events	67,334	36,514
	67,334	36,514
Investments		
Bank interest receivable	6,410	6,947
	6,410	6,947
	115,321	90,441
EXPENDITURE ON:		
Raising funds		
Cost of raising funds	(36,881)	(30,746)
	(36,881)	(30,746)
Charitable Activities:		
Grants to clinical trials		
Grants to clinical trials	(195,000)	-
	(195,000)	-
Share of support costs		
Wages and salaries	(51,467)	(48,840)
Employers pensions - defined contributions scheme	(120)	-
Rent	(1,024)	(956)
Travel costs	(289)	(1,789)
Insurance	(335)	(324)
Printing, postage and stationery	(78)	(111)
Telecommunications	(1,751)	(1,605)
Subscriptions	(404)	(560)
Sundry expenses	(72)	(105)
	(55,540)	(54,290)
Governance costs		
Accountancy fees	(4,971)	(7,553)
Amortisation	(569)	(569)
	(5,540)	(8,122)
	(292,961)	(93,158)
NET EXPENDITURE	(177,640)	(2,717)

